PMID- 38090323 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240214 IS - 2072-1439 (Print) IS - 2077-6624 (Electronic) IS - 2072-1439 (Linking) VI - 15 IP - 11 DP - 2023 Nov 30 TI - Effectiveness and safety of camrelizumab-containing neoadjuvant therapy in patients with esophageal squamous cell carcinoma: a prospective multicenter observational cohort study. PG - 6228-6237 LID - 10.21037/jtd-23-1408 [doi] AB - BACKGROUND: Camrelizumab has been demonstrated to be a feasible treatment option for locally advanced esophageal squamous cell carcinoma (ESCC) when combined with neoadjuvant chemotherapy. This trial was conducted to investigate the effectiveness and safety of camrelizumab-containing neoadjuvant therapy in patients with ESCC in daily practice. METHODS: This prospective multicenter observational cohort study was conducted at 13 tertiary hospitals in Southeast China. Patients with histologically or cytologically confirmed ESCC [clinical tumor-node-metastasis (cTNM) stage I-IVA] who had received at least one dose of camrelizumab-containing neoadjuvant therapy were eligible for inclusion. RESULTS: Between June 1, 2020 and July 13, 2022, 255 patients were enrolled and included. The median age was 64 (range, 27 to 82) years. Most participants were male (82.0%) and had clinical stage III-IVA diseases (82.4%). A total of 169 (66.3%) participants underwent surgical resection; 146 (86.4%) achieved R0 resection, and 36 (21.3%) achieved pathological complete response (pCR). Grades 3-5 adverse events (AEs) were experienced by 14.5% of participants. Reactive cutaneous capillary endothelial proliferation occurred in 100 (39.2%) of participants and all were grade 1 or 2. CONCLUSIONS: Camrelizumab-containing neoadjuvant therapy has acceptable effectiveness and safety profiles in real-life ESCC patients. CI - 2023 Journal of Thoracic Disease. All rights reserved. FAU - Zhang, Yi AU - Zhang Y AD - Department of Cardiothoracic Surgery, Zhangzhou Hospital Affiliated to Fujian Medical University, Zhangzhou, China. FAU - Shen, Guoyi AU - Shen G AD - Department of Cardiothoracic Surgery, Zhangzhou Hospital Affiliated to Fujian Medical University, Zhangzhou, China. FAU - Xu, Rongyu AU - Xu R AD - Department of Thoracic Surgery, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China. FAU - Huang, Guozhong AU - Huang G AD - Department of Thoracic Surgery, Affiliated Hospital of Putian University, Putian, China. FAU - Huang, Zhijun AU - Huang Z AD - Department of Gastrointestinal and Esophageal Surgery, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China. FAU - Duan, Hongbing AU - Duan H AD - Department of Thoracic Surgery, Zhongshan Hospital Affiliated to Xiamen University, Xiamen, China. FAU - Yang, Shengsheng AU - Yang S AD - Depatment of Cardiothoracic Surgery, The 900th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army, Fuzhou, China. FAU - Zheng, Qingfeng AU - Zheng Q AD - Department of Thoracic Surgery, Fujian Cancer Hospital, Fuzhou, China. FAU - Yang, Libao AU - Yang L AD - Department of Thoracic Surgery, Sanming Second Hospital, Sanming, China. FAU - Liu, Rongxing AU - Liu R AD - Depatment of Cardiothoracic Surgery, Longyan Second Hospital, Longyan, China. FAU - Ma, Liangyun AU - Ma L AD - Department of Thoracic Surgery, The 910th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army, Quanzhou, China. FAU - Chen, Shaogeng AU - Chen S AD - Department of Thoracic Surgery, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China. FAU - Yi, Yunfeng AU - Yi Y AD - Depatment of Cardiothoracic Surgery, Southeast Hospital affiliated to Xiamen University, Xiamen, China. FAU - Zhang, Zheming AU - Zhang Z AD - Department of Thoracic Surgery, The 900th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army Putian Medical District, Putian, China. FAU - Li, Kezhi AU - Li K AD - Department of Thoracic Surgery, Nanping First Hospital, Nanping, China. FAU - Birdas, Thomas J AU - Birdas TJ AD - Division of Cardiothoracic Surgery, Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA. FAU - Koyanagi, Kazuo AU - Koyanagi K AD - Department of Gastroenterological Surgery, Tokai University School of Medicine, Kanagawa, Japan. FAU - Simone, Charles B 2nd AU - Simone CB 2nd AD - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center and New York Proton Center, New York, NY, USA. LA - eng GR - P30 CA008748/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20231127 PL - China TA - J Thorac Dis JT - Journal of thoracic disease JID - 101533916 PMC - PMC10713292 OTO - NOTNLM OT - Esophageal squamous cell carcinoma (ESCC) OT - camrelizumab OT - neoadjuvant therapy OT - real world COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-23-1408/coif). The authors have no conflicts of interest to declare. EDAT- 2023/12/13 18:42 MHDA- 2023/12/13 18:43 PMCR- 2023/11/30 CRDT- 2023/12/13 13:07 PHST- 2023/09/08 00:00 [received] PHST- 2023/11/20 00:00 [accepted] PHST- 2023/12/13 18:43 [medline] PHST- 2023/12/13 18:42 [pubmed] PHST- 2023/12/13 13:07 [entrez] PHST- 2023/11/30 00:00 [pmc-release] AID - jtd-15-11-6228 [pii] AID - 10.21037/jtd-23-1408 [doi] PST - ppublish SO - J Thorac Dis. 2023 Nov 30;15(11):6228-6237. doi: 10.21037/jtd-23-1408. Epub 2023 Nov 27.